Testing Nicotinamide Riboside Supplements to Restore Energy in Veterans with Gulf War Illness A Randomized Double-Blind Placebo-Controlled Study for Adults Aged 47 to 70

What this Trial Is About

Researchers are investigating whether a daily 300 mg dose of Nicotinamide Riboside NR, a vitamin B3 family supplement, can increase plasma NAD levels in veterans affected by Gulf War Illness GWI. GWI is a condition affecting about 32% of Gulf War veterans, causing symptoms like memory problems, fatigue, gastrointestinal issues, and widespread pain. The study aims to understand how NR may influence bioenergetic and immune functions in these veterans. Participants are randomly assigned to one of two groups in a double-blind design one group receives 300 mg of NR daily for 10 weeks, while the other group receives a placebo. The study evaluates changes in plasma NAD as the primary outcome and also measures lipid and immune biomarker profiles. Both groups are monitored closely during this 10-week treatment phase. During the study, veterans will have regular assessments including blood tests to measure NAD and other biomarkers. Researchers will also evaluate general health and well-being. The study collects data over the 10-week period to determine if NR supplementation supports healthier bioenergetic profiles. Safety and adherence to the treatment are monitored throughout the trial, which enrolls veterans aged 47 to 70 years with GWI.

Nicotinamide Riboside Clinical Trial for GWI